Fennec Pharmaceuticals Inc (TSE:FRX) shares hit a new 52-week low on Monday . The stock traded as low as C$5.97 and last traded at C$6.16, with a volume of 6290 shares trading hands. The stock had previously closed at C$6.50.
The company has a market cap of $129.32 million and a price-to-earnings ratio of -11.65.
Fennec Pharmaceuticals (TSE:FRX) last announced its earnings results on Wednesday, March 13th. The biopharmaceutical company reported C($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.18) by C($0.02).
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Story: Why is the LIBOR significant?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.